ARDSLEY, N.Y. – Acorda Therapeutics, Inc. recently announced Michael Rogers has joined the company as chief financial officer and former CFO David Lawrence has been named chief of business operations.
“I’m delighted to welcome Mike Rogers to Acorda’s senior management team. Mike has a record of success as CFO at both commercial- and development-stage biotechnology companies, as well as a background in investment banking,” said Ron Cohen, Acorda’s president and chief executive officer in a prepared statement. “Mike’s strategic insight and broad experience will help us capitalize on opportunities to expand Acorda’s business and continue to deliver shareholder value.”
Rogers joins Acorda with 22 years experience in the biopharmaceutical industry. Most recently, he served as executive vice president and CFO of BG Medicine, Inc., where he led the company’s successful initial public offering in 2011 and was instrumental in assisting in
the launch of that company’s first product in the cardiovascular area. Prior to that, Rogers
served as the CFO of Indevus Pharmaceuticals for 10 years until the company’s sale to Endo
“Acorda is now at a stage that requires focused leadership of our business operations," Cohen said in the statement. "Dave has been a key contributor to building the company over the last 15 years, and we are fortunate to continue to benefit from his capabilities as he expands his role within Acorda.”